Sarepta Therapeutics Takes a Major Step Forward in Huntington's Disease Treatment

On January 7, 2026, Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a pioneer in precision genetic medicine focusing on rare diseases, announced the submission of a Clinical Trial Application (CTA) for its investigational treatment, SRP-1005, targeting Huntington’s Disease. The application has been submitted to Medsafe, the New Zealand Medicines and Medical Devices Safety Authority, marking a significant milestone in the company’s research and development efforts.

Pending regulatory approval, Sarepta plans to initiate the first-in-human clinical trial, known as Study SRP-1005-101 or INSIGHTT, in the second quarter of 2026. This trial is expected to pave the way for new therapeutic avenues for Huntington's Disease, a condition that currently has no approved treatments aimed at slowing or halting its progression.

Huntington's Disease (HD) is a hereditary neurodegenerative disorder that leads to the progressive deterioration of nerve cells in the brain. Affecting approximately 40,000 individuals in the U.S., with an additional 200,000 at risk of developing symptoms, the disease manifests typically between the ages of 30 and 50. Symptoms worsen over time, significantly impacting cognition, movement, and behavior, and placing an emotional and physical burden on families across generations.

Dr. Louise Rodino-Klapac, Sarepta's president of research & development and technical operations, emphasized the dire need for innovative treatment options, stating, “Huntington’s disease is a devastating, progressive condition with extremely limited therapeutic options and no approved treatments to slow or halt its course. The need for new approaches is urgent.”

The INSIGHTT trial is a Phase 1, multi-center, dose escalation study designed to assess the safety and tolerability of subcutaneous dosing of SRP-1005 in approximately 24 participants. This innovative siRNA (small interfering RNA) therapeutic aims to target the deep brain regions affected by Huntington's Disease, utilizing a TfR1 (transferrin receptor protein 1) approach. This method employs monovalent fragment antigen binding (fAb) allowing for more efficient delivery to the central nervous system.

One of the key advantages of subcutaneous delivery is its potential to maintain levels below transferrin saturation, facilitating consistent and robust penetration across the blood-brain barrier. Preclinical data have shown promising results, indicating significant protein knockdown in essential brain regions, including the putamen and caudate, as well as the temporal and frontal cortexes.

Sarepta's commitment to addressing neurodegenerative diseases is underscored by its next-generation siRNA platform, which includes investigational treatments for various conditions beyond Huntington's Disease. The portfolio features therapies targeting:

Additionally, Sarepta is advancing preclinical programs for Spinocerebellar ataxia types 1 and 3 (SCA1 and SCA3), along with an exclusive collaboration with Arrowhead Pharmaceuticals for therapies addressing skeletal muscle diseases.

Sarepta Therapeutics stands at the forefront of innovation in genetic medicine, with a mission to develop targeted therapies that tackle the root causes of rare diseases. The submission of the CTA for SRP-1005 is a testament to the company's dedication and urgency in providing solutions for conditions that currently have no effective treatments.

As Sarepta prepares for the next steps in its clinical journey, stakeholders and investors will be closely watching the developments surrounding INSIGHTT and the potential impact of SRP-1005 on the landscape of Huntington's Disease treatment. The journey is just beginning, but hope is on the horizon for families affected by this devastating condition.